drugset / Trial / NCT02826070

Summary

The purpose of this study is to demonstrate that long-term treatment (up to six years) with telbivudine or telbivudine plus adefovir results in the regression in liver inflammation and fibrosis/cirrhosis.

Timeline

Start
2015-04
Primary completion
2016-10
Completion
2017-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Adefovir dipivoxil Small molecule 10 mg Oral
Subject Telbivudine Small molecule 600 mg Oral